NDA submission to the FDA marks a pivotal step toward U.S. market entry, while profitability improved despite flat group sales. Strong growth in Spain, France, and the U.K. offset declines in Germany, and cash burn is expected to decrease as U.S. regulatory costs subside.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.